Literature DB >> 9710743

pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.

L K Gordon1, M Eggena, G N Holland, J M Weisz, J Braun.   

Abstract

A pANCA autoantibody (antineutrophil cytoplasmic antibody, perinuclear pattern) has been described in uveitis patients, but its correlation with systemic illnesses and the specific type of pANCA has not been defined. The goals of this study were to determine the (1) frequency of pANCA autoantibodies in uveitis, (2) systemic associations in the pANCA + uveitis patients, and (3) type of pANCA antigen recognized by the uveitis-associated autoantibody. Serum was obtained from 59 patients with anterior uveitis or panuveitis and from nonuveitis controls. A detailed medical and family history was obtained from each subject at the time of phlebotomy. Sera were screened by neutrophil ELISA to determine the frequency of ANCA positivity. Immunofluorescence assays were then used to differentiate cANCA from pANCA. The specificity of the pANCA + antibodies was further characterized by DNase 1 sensitivity and granule antigen ELISAs. ANCA antibodies were detected in 29% of all patients with panuveitis or anterior uveitis. In 41% of these ANCA + patients, serum antibody detected a perinuclear antigen that was sensitive in all cases to DNase 1. The majority of pANCA + uveitis patients were either HLA-B27 positive or had systemic evidence of immune-mediated diseases. Two pANCA + patients had no medical or family history of other immune-mediated diseases. This study identifies a subset of uveitis patients distinguished by expression of a specific pANCA marker antibody. The characteristics of this antibody are similar to the pANCA antibody present in most patients with ulcerative colitis. Expression of the pANCA autoantibody in uveitis patients is a susceptibility marker for other immune-mediated diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710743     DOI: 10.1023/a:1027333822801

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  44 in total

Review 1.  Acute dacryoadenitis and Crohn's disease: findings and management.

Authors:  S Dutt; M J Cartwright; C C Nelson
Journal:  Ophthalmic Plast Reconstr Surg       Date:  1992       Impact factor: 1.746

Review 2.  Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations.

Authors:  D R Schultz; E C Tozman
Journal:  Semin Arthritis Rheum       Date:  1995-12       Impact factor: 5.532

3.  Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type.

Authors:  J Sobajima; S Ozaki; T Okazaki; F Osakada; S Sumita; K Mori; K Nakao
Journal:  Clin Exp Immunol       Date:  1996-07       Impact factor: 4.330

4.  Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1.

Authors:  T Orth; G Gerken; R Kellner; K H Meyer zum Büschenfelde; W J Mayet
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

Review 5.  Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences.

Authors:  E C Hagen; B E Ballieux; L A van Es; M R Daha; F J van der Woude
Journal:  Blood       Date:  1993-04-15       Impact factor: 22.113

6.  Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis.

Authors:  F Seibold; D Slametschka; M Gregor; P Weber
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

7.  Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients.

Authors:  C Geffriaud-Ricouard; L H Noël; D Chauveau; S Houhou; J P Grünfeld; P Lesavre
Journal:  Clin Nephrol       Date:  1993-03       Impact factor: 0.975

8.  Autoantibodies to protein tyrosine phosphatase-like proteins in type I diabetes. Overlapping specificities to phogrin and ICA512/IA-2.

Authors:  E Kawasaki; G S Eisenbarth; C Wasmeier; J C Hutton
Journal:  Diabetes       Date:  1996-10       Impact factor: 9.461

Review 9.  Clinical features and associated systemic diseases of HLA-B27 uveitis.

Authors:  M L Tay-Kearney; B L Schwam; C Lowder; J P Dunn; D M Meisler; S Vitale; D A Jabs
Journal:  Am J Ophthalmol       Date:  1996-01       Impact factor: 5.258

10.  Anti-neutrophil cytoplasmic antibodies in chronic inflammatory bowel disease. Prevalence and diagnostic role.

Authors:  E Hertervig; J Wieslander; C Johansson; A Wiik; A Nilsson
Journal:  Scand J Gastroenterol       Date:  1995-07       Impact factor: 2.423

View more
  4 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort Study.

Authors:  Adam V Weizman; Brian Huang; Stephan Targan; Marla Dubinsky; Phillip Fleshner; Manreet Kaur; Andrew Ippoliti; Deepa Panikkath; Eric Vasiliauskas; David Shih; Dermot P B McGovern; Gil Y Melmed
Journal:  J Cutan Med Surg       Date:  2014-10       Impact factor: 2.092

3.  The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease.

Authors:  Nuran Turkcapar; Murat Toruner; Irfan Soykan; Olcay Tiryaki Aydintug; Hulya Cetinkaya; Nursen Duzgun; Ali Ozden; Murat Duman
Journal:  Rheumatol Int       Date:  2005-09-01       Impact factor: 2.631

Review 4.  Eye manifestations in patients with perinuclear antineutrophil cytoplasmic antibody-associated vasculitis: case series and literature review.

Authors:  Toshihiko Matsuo
Journal:  Jpn J Ophthalmol       Date:  2007-04-06       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.